阿德福韦酯联合苦参素治疗慢性乙型肝炎肝纤维化疗效观察  

Clinical study of Adefovir dipivoxil combined with matrine soft capsule in the treatment of chronic hepatitis B patients with liver fibrosis

作　　者：刘钦[1] 张小帆[1] 刘红[1] 高扬[1] 

机构地区：[1]广东省深圳市第三人民医院,518020

出　　处：《中国医学创新》2010年第17期45-46,共2页Medical Innovation of China

摘　　要：目的评价阿德福韦酯联合苦参素治疗慢性乙型肝炎肝纤维化的临床效果及用药安全性,探讨临床慢性乙型肝炎肝纤维化治疗方法。方法选择85例慢性乙型肝炎肝纤维化患者随机分成:治疗组45例,给予阿德福韦酯10 mg/d,加上苦参素200 mg,3次/d口服;对照组40例,给予阿德福韦酯10 mg/d口服,疗程12个月。分别观察两组慢性乙型肝炎肝纤维化患者治疗前后的临床症状、体征改善状况,生化应答率、病毒应答率、肝纤维化指标改善情况和临床副作用。结果治疗组肝纤维化指标改善情况与对照组比较统计学上差异有显著意义(P均<0.01)。结论阿德福韦酯联合苦参素,可明显改善慢性乙型肝炎肝纤维化指标。Objective To evaluate the effect of adefovir dipivoxil combined with matrine soft capsule on chronic hepatitis B patients with liver fibrosis, and to research the therapy method of this disease. Methods Eighty - five cases of chronic hepatitis B patients with liver fibrosis were randomly divided into 2 groups. The treatment group was treated with adefovir dipivoxil 10 mg/d combined with matrinc soft capsule 200 mg 3 times a day. The control group was only with adefovir dipivoxil 10 mg/d. The treatment course of 2 groups was 12 months. Results Compared with the control group, the improvement of liver fibrosis indexes in the treatment group was more obvious（ P 〈 0.01 ）. Conclusion Adefovir dipivoxil combined with matrine soft capsule can obviously improve the liver fibrosis indexes in chronic hepatitis B patients with liver fibrosis.

关 键 词：阿德福韦酯 苦参素 慢性乙型肝炎肝纤维化 

分 类 号：R512.62[医药卫生—内科学]